Showing 3891-3900 of 5646 results for "".
- EyeSouth Partners Affiliates with Retina and Vitreous of Texashttps://modernod.com/news/eyesouth-partners-affiliates-with-retina-and-vitreous-of-texas/2481807/EyeSouth Partners has announced that it has partnered with Retina and Vitreous of Texas (RVT), in Houston. The affiliation represents EyeSouth’s 38th overall and the network’s first retina-only affiliation in the state of Texas. Financial terms of the deal were not disclosed
- OcuCell Secures Funding from The Eye-Bank for Sight Restorationhttps://modernod.com/news/ocucell-secures-funding-from-the-eye-bank-for-sight-restoration/2481804/Ocular cell therapy company OcuCell announced it has received seed funding from The Eye-Bank for Sight Restoration (EBSR). The funding will enable OcuCell to accelerate its mission of transforming the corneal cell therapy landscape through the development of cell therapy solut
- Atsena Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-of-atsn-201-for-the-treatment-of-x-linked-retinoschisis/2481796/Atsena Therapeutics announced the first patient has been dosed in the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 uses AAV.SPR, the company’s novel spreading c
- ScienceBased Health Welcomes New Members to Its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-welcomes-new-members-to-its-optometry-clinical-advisory-panel/2481787/ScienceBased Health (SBH) announced the addition of Jaclyn Garlich, OD, FAAO; Jacob Lang, OD, FAAO, Dipl ABO; and Mark Schaeffer, OD to its Optometry Clinical Advisory Panel. ScienceBased Health develops and markets e
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat RPhttps://modernod.com/news/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/2481784/ViGeneron announced that the European Medicines Agency (EMA) has approved the clinical trial application for VG901, a gene therapy to treat CNGA1-associated retinitis pigmentosa (RP). VG901 uses vgAAV, ViGeneron's proprietary adeno-associated virus (AAV) vector to deliver the CNGA1
- FDA Approves Regeneron's High-Dose Aflibercept, Eylea HDhttps://modernod.com/news/fda-approves-regenerons-high-dose-aflibercept-eylea-hd/2481782/In a major move that is expected to significantly extend dosing intervals for patients with retinal diseases, Regeneron received FDA approval for Eylea HD (aflibercept 8 mg) for patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic reti
- NEI: Scientists Discover External Protein Network Can Help Stabilize Neural Connectionshttps://modernod.com/news/nei-scientists-discover-external-protein-network-can-help-stabilize-neural-connections/2481781/The Noelin family of secreted proteins bind to the external portion of AMPA glutamate receptors and stabilize them on the neuronal cellular membrane, a process necessary for transmission of full-strength signals between neurons, according to a study in mice from the National Eye Institute (NEI) a
- Sandoz Announces Results from Mylight Phase 3 Study for Biosimilar Aflibercepthttps://modernod.com/news/sandoz-announces-results-from-mylight-phase-3-study-for-biosimilar-aflibercept/2481777/Sandoz released positive results from the MYLIGHT phase 3 confirmatory efficacy and safety study for its biosimilar aflibercept for wet macular degeneration (AMD). The Mylight phase 3 confirmatory efficacy and safety study (ClinicalTrials.gov NCT04864834) met its pri
- Bonnie Henderson, MD, Named Interim President and CEO of HelpMeSeehttps://modernod.com/news/bonnie-henderson-md-named-interim-president-and-ceo-of-helpmesee/2481776/Bonnie Henderson, MD, has been named interim president and CEO of global nonprofit HelpMeSee. HelpMeSee provides cataract treatment training using its simulation-based training system with the aim of increasing access to treatment and eradicating cataract blindness. &nbs